KAIROS PHARMA LTD (KAPA)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.84+10.18%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KAPA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue clinical development of ENV-105 targeting drug resistance in EGFR-mutated NSCLC and prostate cancer with ongoing Phase 1 and Phase 2 trials.
Newly stated in 2026-Q2. Management reported interim Phase 1 safety data for ENV-105 in EGFR-mutated lung cancer and ongoing Phase 2 prostate cancer trial with median progression-free survival exceeding 13 months. No prior quarters in the supplied data mention this priority, so trajectory is newly established.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients”
Pursue acquisition and development of CL-741, a candidate targeting EGFR-mutated lung cancer, with planned Phase 1 study initiation in 2026.
Newly stated in 2026-Q2. Management disclosed acquisition of CL-273 assets and plans for Phase 1 study initiation with CL-741 in 2026. No financial metrics are available to assess progress; trajectory is newly established.
“Anticipate initiation of Phase 1 study with CL-741 targeting EGFR-mutated lung cancer”
Engage in collaboration with Bayer to support research on radium combined with ENV-105 for prostate cancer bone metastasis.
Newly stated in 2026-Q2. Management announced collaboration with Bayer to support research combining radium and ENV-105 in prostate cancer. No financial or operational metrics are available to assess progress; trajectory is newly established.
“Entered into agreement with Bayer for radium use in study with ENV-105 in prostate cancer bone metastasis”
Continue disciplined cost management to sustain low cash burn and seek non-dilutive funding sources.
Not explicitly stated in the supplied transcripts for the last six quarters. Financials show quarterly cash burn between $714K and $1,012K, indicating ongoing cash outflows consistent with clinical-stage operations. Without explicit management statements in these quarters, progress on this priority cannot be fully assessed.
Implement a 1-for-7 reverse stock split to increase per-share price and maintain exchange listing standards.
Newly stated in 2026-Q3. Management announced a 1-for-7 reverse stock split effective September 1, 2026, aimed at increasing per-share price to maintain NYSE American listing compliance. This is a one-time capital structure action with no prior quarters mentioning it.
“Announced 1-for-7 reverse stock split effective September 1, 2026 to maintain NYSE American listing”
Over the trailing year it converted 0.54x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
14 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.